Abstract

Background: Congenital heart disease (CHD) is the most common congenital anomaly and the leading cause of neonatal mortality. Measurement of serum hs-Troponin T levels plays an important role in detecting progressive myocardial injury in CHD, thereby contributing to disease monitoring and prognosis. Objective: To describe serum hs-Troponin T levels and investigating their association with the clinical characteristics of CHD in neonates. Materials and methods: A cross-sectional study was conducted on 102 neonates diagnosed with CHD by color Doppler echocardiography, admitted to the Pediatric Center – Hue Central Hospital between May 2023 and August 2025. Results: The median serum hs-Troponin T level was 0.093 ng/mL. Significantly higher hs-Troponin T concentrations were observed in preterm neonates, and in those with heart failure or pulmonary hypertension (p < 0.05). ROC curve analysis identified a cutoff value of 0.0345 ng/mL for predicting mortality, with a sensitivity of 94.7% and a specificity of 28.1% (AUC = 0.626; p = 0.034). 252 TẠP CHÍ Y DƯỢC HUẾ - HUE JOURNAL OF MEDICINE AND PHARMACY ISSN 3030-4318; eISSN: 3030-4326 Conclusions: hs-Troponin T is a valuable biomarker for assessing complications of CHD in neonates; however, its ability to predict mortality in this patient group remains limited.